Germline Pharmacogenetics - PGx

Germline pharmacogenetics describes genetic variations associated with drug response or drug disposition that may predispose a patient to be at risk for drug-related toxicity, nonstandard dose requirements, or lack of therapeutic benefit. The goals of pharmacogenetic testing are to reduce the high number of nonresponders (averaging 30-60% of patients) and to prevent or reduce adverse drug reactions.

ARUP offers single gene testing with predicted pharmacogenetic phenotypes as well as a genotype panel that codes for drug metabolizing enzymes. The panel includes a comprehensive report of drug recommendations and access to a medication risk management tool.

Tabs Content

Last Update: June 2018